Protein / target

Mu-type opioid receptor

OPRM1P35372Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
72
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Voltage-gated calcium channel activity

Primary system

Nervous system

Strongest disease association

opioid use disorder

Genetic evidence · score 0.84

Therapeutic maturity

Clinically validated target

72 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Approved Drug

Clinical development

72 approved · 16 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G protein complex and subsequent exchange of GDP for GTP in the G protein alpha subunit leading to dissociation of the G protein complex with the free GTP-bound G protein alpha and the G protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G protein-coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)

Subcellular location

Cell membraneCell projection, axonPerikaryonCell projection, dendriteEndosomeCytoplasm
Domains and Gene Ontology detail (34)

Gene Ontology

  • Caxon
  • Cdendrite
  • Cendoplasmic reticulum
  • Cendosome
  • CGolgi apparatus
  • Cneuron projection
  • Cperikaryon
  • Cplasma membrane
  • Csynapse
  • Fbeta-endorphin receptor activity
  • FG protein-coupled receptor activity
  • FG-protein alpha-subunit binding

400 aa · 45 kDa · 18 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

G protein-coupled signallingUniProt · GOSynaptic signallingGOKinase signallingUniProtImmune signallingReactome
View supporting evidence

G protein-coupled signalling

  • ·Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478,…
  • ·G protein-coupled receptor activity
  • ·adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway
  • ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway

Synaptic signalling

  • ·synapse

Kinase signalling

  • ·Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478,…

Immune signalling

  • ·Interleukin-4 and Interleukin-13 signaling
View underlying pathways (6)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PENKPOMCGNAI1PDYNARRB2ARRB1OPRD1GRK2GRK6GRK5OPRM1

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

5

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Fentanyl
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Appears in clinical studies involving Chronic pain, Pain, cancer, pain agnosia

Direct interaction with this protein · Only this protein recorded as a target

Buprenorphine
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Appears in clinical studies involving drug dependence, opiate dependence, overdose, Chronic pain

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

Oxycodone
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Appears in clinical studies involving Pain, Chronic pain, drug dependence, Back pain

Direct interaction with this protein · Only this protein recorded as a target

Heroin
Narrow target profileAgonist

Mu opioid receptor agonist

Direct interaction with this protein · Only this protein recorded as a target

Naltrexone
ApprovedAntagonist

Opioid receptors; mu/kappa/delta antagonist

Appears in clinical studies involving alcohol dependence, Overweight, Obesity, Borderline personality disorder

Acts on a complex — shared with OPRK1, OPRD1 · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

opioid use disorder0.84

Genetic · overall 0.62

opiate dependence0.54

Genetic · overall 0.69

Pain0.53

Genetic · overall 0.69

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

Chronic pain1.00

Clinical · overall 0.61

alcohol dependence0.99

Clinical · overall 0.61

Diarrhea0.99

Clinical · overall 0.60

drug dependence0.98

Clinical · overall 0.60

Constipation0.98

Clinical · overall 0.60

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

cancer0.62

Clinical

migraine disorder0.60

Clinical

Show all associations
opiate dependence0.69
Pain0.69
opioid use disorder0.62
cancer0.62
alcohol dependence0.61
Chronic pain0.61
drug dependence0.60
Diarrhea0.60
migraine disorder0.60
Constipation0.60

Open Targets ranks 751 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 88 total

MEPERIDINE HYDROCHLORIDEApproval

Pain · drug dependence

HYDROCODONEApproval

Pain · Cough · Chronic pain

NALOXONE HYDROCHLORIDE DIHYDRATEApproval

opiate dependence

NALOXEGOLApproval

Constipation · Pain · gastroparesis

NALOXEGOL OXALATEApproval

constipation disorder · Pain · Constipation

METHYLNALTREXONEPhase 3

Constipation · Constipation · acute pancreatitis

CEBRANOPADOLPhase 3

diabetic neuropathy · cancer pain · Pain

FENTANYLApproval

Chronic pain · Pain · cancer

LEVALLORPHANApproval
MEPERIDINEApproval

Pain · postpartum depression · acute graft versus host disease

Tractability

SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Small Molecule BinderOC · Advanced Clinical

Safety liabilities

quality of sleepnicotine dependenceneurotoxicitydecreased gastric emptyingdecreased anxietyopioid-induced adverse effects, opioid-induced nausea and vomitinggasdecreased gastrointestinal transittreatment emergent suicidal ideation (TESI)sleep apneadecreased cardiac outputdecreased gastrointestinal motility

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

COMPLETED · via Naltrexone · NCT00270231

COMPLETED · via Buprenorphine · NCT00000230

COMPLETED · via Naltrexone · NCT02107014

WITHDRAWN · via Naltrexone · NCT00398008

COMPLETED · via Oxycodone · NCT04587115

COMPLETED · via Buprenorphine · NCT00000239

TERMINATED · via Buprenorphine · NCT03605342

RECRUITING · via Oxycodone · NCT07348627

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

opioid use disorderWell supported
0.93
agreement 0.821.00
Genetic61%Clinical37%Literature2%

Open Targets aggregate 0.62 · 3 independent evidence families

opiate dependenceWell supported
0.89
agreement 0.781.00
Clinical55%Genetic40%Literature4%

Open Targets aggregate 0.69 · 3 independent evidence families

PainWell supported
0.88
agreement 0.780.99
Clinical58%Genetic41%Literature1%

Open Targets aggregate 0.69 · 3 independent evidence families

cancerWell supported
0.76
agreement 0.610.92
Clinical85%Literature15%

Open Targets aggregate 0.62 · 2 independent evidence families

alcohol dependenceWell supported
0.76
agreement 0.600.91
Clinical92%Literature8%

Open Targets aggregate 0.61 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

60

Recent activity around this target, drawn from one canonical event stream. Every item is reached through 4 drugs that target this protein, so each event is news about that drug rather than about the protein directly.

  1. Label change2026-07-13

    Label change: BUPRENORPHINE (ANDA204937)

    fda · regulatory · fda · via Buprenorphine

  2. Label change2026-07-13

    Label change: BUPRENORPHINE (ANDA204937)

    fda · regulatory · fda · via Buprenorphine

  3. Label change2026-07-13

    Label change: BUPRENORPHINE (ANDA204937)

    fda · regulatory · fda · via Buprenorphine

  4. Industry development2026-07-07
    Many U.S. teens underestimate fentanyl’s deadly risk

    Science News · news · via Fentanyl

  5. Supplemental approval2026-06-18

    Supplemental approval: BUPRENORPHINE (ANDA207490)

    fda · regulatory · fda · via Buprenorphine

  6. Supplemental approval2026-06-18

    Supplemental approval: FENTANYL (ANDA202097)

    fda · regulatory · fda · via Fentanyl

  7. Supplemental approval2026-06-18

    Supplemental approval: OXYCODONE AND ACETAMINOPHEN (ANDA210644)

    fda · regulatory · fda · via Oxycodone

  8. Supplemental approval2026-06-18

    Supplemental approval: BUPRENORPHINE (ANDA210272)

    fda · regulatory · fda · via Buprenorphine

  9. Supplemental approval2026-06-18

    Supplemental approval: BUPRENORPHINE (ANDA211586)

    fda · regulatory · fda · via Buprenorphine

  10. Supplemental approval2026-06-18

    Supplemental approval: BUPRENORPHINE (ANDA204937)

    fda · regulatory · fda · via Buprenorphine

  11. Supplemental approval2026-06-18

    Supplemental approval: BUPRENORPHINE (ANDA210162)

    fda · regulatory · fda · via Buprenorphine

  12. Supplemental approval2026-06-18

    Supplemental approval: OXYCODONE (NDA208090)

    fda · regulatory · fda · via Oxycodone

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.